





Substitute for form 1449/PTO		<div style="text-align: center;">  </div>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/656,981
		Filing Date	September 5, 2003
		First Named Inventor	Scott C. Mayer
		Group Art Unit	
Examiner Name			
Sheet	1	of	1
		Attorney Docket Number	AM100893

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
<i>[Signature]</i>	1.	6,211,244	B1		04-03-2001	
<i>[Signature]</i>	2.	6,031,003			02-29-2000	
<i>[Signature]</i>	3.	6,001,884			12-14-1999	
<i>[Signature]</i>	4.	6,143,789			11-07-2000	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	5.	JP	2000-178243			06-27-2000		<input checked="" type="checkbox"/>
	6.	WO	00/21920			04-20-2000		<input type="checkbox"/>
	7.	WO	95/11221			04-27-1995		




OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
<i>[Signature]</i>	8.	REAVEN, et al., "Nonketotic Diabetes Mellitus: Insulin Deficiency or Insulin Resistance?", American Journal of Medicine, (Jan 1976), Vol. 60, pp 80-88	<input type="checkbox"/>
	9.	STOUT, Metabolism: Clinical & Experimental, (Dec. 1985), 34 (12 Suppl 1): 7-12, (Abstract)	<input type="checkbox"/>
	10.	PYORALA, et al., Diabetes/Metabolism Reviews, "Diabetes and Atherosclerosis: An Epidemiologic View", (1987), Vol. 3, pp 463-524	<input type="checkbox"/>
	11.	JARRETT, R. J., et al Diabetes/Metabolism Review, "Cardiovascular Disease and Hypertension in Diabetes Mellitus", (1989), Vol. 5, No 7, 547-558	<input type="checkbox"/>
	12.	HARRIS, et al., Diabetes in America, "Mortality From Diabetes", Chapter 29, pp 1-48, (1985)	<input type="checkbox"/>
	13.	DEFRONZO and FERRANNINI, Diabetes Care, "Insulin resistance.", (March 1991), 14, 173-194 (Abstract)	<input type="checkbox"/>
<i>[Signature]</i>	14.	HARING, Diabetologia, "The insulin receptor: signalling mechanism and contribution to the pathogenesis of insulin resistance", (1991), 34, 848-861 (Abstract)	<input type="checkbox"/>
	15.	B.J. GOLDSTEIN, J. Cellular Biochemistry, "Protein-tyrosine phosphatases and the regulation of insulin action", (1992), 48, 33 (Abstract)	<input type="checkbox"/>
	16.	B.J. GOLDSTEIN, Receptor, "Reg. of insulin receptor signaling by protein-tyrosine dephosphorylation", (1993), 3, 1-15 (Abstract)	<input type="checkbox"/>
<i>[Signature]</i>	17.	F. AHMAD and B.J. GOLDSTEIN Biochim. Biophys Acta, "Purification, identification and subcellular distribution of three predominant protein-tyrosine phosphatase enzymes in skeletal muscle tissue", (1995), 1248, 57-69 (Abstract)	<input type="checkbox"/>
	18.	McGUIRE, et al., Diabetes, "Abnormal Regulation of Protein Tyrosine Phosphatase Activities in Skeletal Muscle of Insulin-Resistant Humans", (1991), Vol. 40, 939-942	<input type="checkbox"/>
	19.	MEYEROVITCH, et al., J. Clinical Invest., "Hepatic phosphotyrosine phosphatase activity and its alterations in diabetic rats", (1989), Vol. 84, 976-983 (Abstract)	<input type="checkbox"/>
<i>[Signature]</i>	20.	SREDY, et al Metabolism: Clinical & Experimental, "Insulin resistance is associated with abnormal dephosphorylation of a synthetic phosphopeptide corresponding to the major autophosphorylation sites of the insulin receptor", 44, 1074-1081 1995 (Abstract)	<input type="checkbox"/>

Examiner Signature	<i>[Signature]</i>	Date Considered	9/2004
--------------------	--------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/656,981
(use as many sheets as necessary)		Filing Date	September 5, 2003
		First Named Inventor	Scott C. Mayer
		Group Art Unit	
		Examiner Name	
Sheet	1 of 1	Attorney Docket Number	AM100893

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
<i>MS</i>	1.	6,211,244	B1		04-03-2001	
<i>MS</i>	2.	6,031,003			02-29-2000	
<i>MS</i>	3.	6,001,884			12-14-1999	
<i>MS</i>	4.	6,143,789			11-07-2000	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	5.	JP	2000-178243			06-27-2000		<input checked="" type="checkbox"/>
	6.	WO	00/21920			04-20-2000		<input type="checkbox"/>
	7.	WO	95/11221			04-27-1995		

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T
M	8.	REAVEN, et al., "Nonketotic Diabetes Mellitus: Insulin Deficiency or Insulin Resistance?", American Journal of Medicine, (Jan 1976), Vol. 60, pp 80-88		<input type="checkbox"/>
	9.	STOUT, Metabolism: Clinical & Experimental, (Dec. 1985), 34 (12 Suppl 1): 7-12, (Abstract)		<input type="checkbox"/>
	10.	PYORALA, et al., Diabetes/Metabolism Reviews, "Diabetes and Atherosclerosis: An Epidemiologic View", (1987), Vol. 3, pp 463-524		<input type="checkbox"/>
	11.	JARRETT, R. J., et al Diabetes/Metabolism Review, "Cardiovascular Disease and Hypertension in Diabetes Mellitus", (1989), Vol. 5, No 7, 547-558		<input type="checkbox"/>
M	12.	HARRIS, et al., Diabetes in America, "Mortality From Diabetes", Chapter 29, pp 1-48, (1985)		<input type="checkbox"/>
	13.	DEFRONZO and FERRANNINI, Diabetes Care, "Insulin resistance.", (March 1991), 14, 173-194 (Abstract)		<input type="checkbox"/>
	14.	HARING, Diabetologia, "The insulin receptor: signalling mechanism and contribution to the pathogenesis of insulin resistance", (1991), 34, 848-861 (Abstract)		<input type="checkbox"/>
	15.	B.J. GOLDSTEIN, J. Cellular Biochemistry, "Protein-tyrosine phosphatases and the regulation of insulin action", (1992), 48, 33 (Abstract)		<input type="checkbox"/>
M	16.	B.J. GOLDSTEIN, Receptor, "Reg. of insulin receptor signaling by protein-tyrosine dephosphorylation", (1993), 3, 1-15 (Abstract)		<input type="checkbox"/>
	17.	F. AHMAD and B.J. GOLDSTEIN Biochim. Biophys Acta, "Purification, identification and subcellular distribution of three predominant protein-tyrosine phosphatase enzymes in skeletal muscle tissue", (1995), 1248, 57-69 (Abstract)		<input type="checkbox"/>
	18.	McGUIRE, et al., Diabetes, "Abnormal Regulation of Protein Tyrosine Phosphatase Activities in Skeletal Muscle of Insulin-Resistant Humans", (1991), Vol. 40, 939-942		<input type="checkbox"/>
	19.	MEYEROVITCH, et al., J. Clinical Invest., "Hepatic phosphotyrosine phosphatase activity and its alterations in diabetic rats", (1989), Vol. 84, 976-983 (Abstract)		<input type="checkbox"/>
M	20.	SREDY, et al Metabolism: Clinical & Experimental, "Insulin resistance is associated with abnormal dephosphorylation of a synthetic phosphopeptide corresponding to the major autophosphorylation sites of the insulin receptor", 44, 1074-1081 1995 (Abstract)		<input type="checkbox"/>

Examiner Signature	<i>Ki/lo</i>	Date Considered	9/2004
--------------------	--------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.